Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study)
Abstract Background Brodalumab, a fully human anti‐interleukin (IL)‐17 monoclonal antibody that blocks IL‐17RA, is approved in Europe for the treatment of adult patients with moderate‐to‐severe plaque psoriasis who are candidates for systemic treatment. Objectives This study evaluated the achievemen...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | JEADV Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.1002/jvc2.204 |